|
|
 |
Registry of Lobbyists - Dominic Falconi
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 3152 | Active | | | Initial registration date | Last date of any changes | | 24-April-2024 | 24-April-2024 |
|
Lobbyist's Last Name
Falconi |
Lobbyist's First Name
Dominic |
Middle Initial
|
|
Business Address of Lobbyist
8401 Trans-Canada Highway |
City
Saint-Laurent |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H4S 1Z1 |
Telephone
5142923504 |
Fax
|
| |
Business or Firm Name for Lobbyist (if applicable)
AbbVie Corporation |
Registry of Joint Stock Companies Number
|
Business Address of Lobbyist's Business or Firm
8401 Trans-Canada Highway |
City
Saint-Laurent |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H4S 1Z1 |
Telephone
5142923504 |
Fax
|
|
|
No other beneficiaries of lobbying activities
|
|
|
|
Description of Employer's Business:
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca. |
| |
|
|
|
| Description |
|
| AbbVie Corporation engages the Nova Scotia government to advocate for policies that support timely access to AbbVie’s innovative medicines for appropriate patients More specifically, we engage with government to:
• Advocate for the value of innovative pharmaceuticals in improving patient outcomes and overall savings to the healthcare system, as well as advancing health security and economic growth.
• Identify partnership opportunities with the Government of Nova Scotia, Regional Health Authorities, and Universities in clinical research on new and existing treatments and therapies, and the generation of real-world evidence.
• Help support health system improvements and healthcare outcomes.
• Advocate for pharmaceutical pricing and reimbursement policies that reflect the value of new medicines to patients and the health care system. |
View
|
|
|
|
|
|
No funding from any government or agency
|
|
No private funding related to lobbying activities
|
|
|
|
|
